Shanghai Fosun Pharmaceutical has announced a plan to repurchase its H-shares for up to HK$1 billion, a move aimed at boosting shareholder returns and demonstrating confidence in its intrinsic value. The repurchased shares will be cancelled or held as treasury shares, with the program effective immediately and to be implemented as soon as practicable. Funding will primarily come from the proceeds of selling about 6% of its stake in Gland Pharma for roughly US$294 million, after which Fosun Pharma will retain a 45.76% interest and continue to consolidate Gland Pharma. In the first half of 2026, Fosun Pharma reported revenue of RMB 20,442 million, up 4.75% year-on-year, and net profit attributable to shareholders excluding non-recurring items of RMB 1,144 million, up 19.09%.
Shanghai Fosun Pharmaceutical Group Co LtdFosun Pharma announced an up-to-HK$1 billion H-share buyback funded by Gland Pharma stake sale proceeds, boosting shareholder returns.
Fosun Pharma is selling about 6% of Gland Pharma for ~US$294 million but will retain 45.76% and continue consolidating it.
